Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Clin. biomed. res ; 42(2): 112-120, 2022.
Artigo em Português | LILACS | ID: biblio-1391470

RESUMO

Introdução: A pediatria apresenta um cenário bastante específico devido ao uso de medicamentos off-label e carência de estudos científicos direcionados à utilização de medicamentos por essa população. Assim, o farmacêutico clínico pode contribuir na identificação e prevenção de problemas relacionados a medicamentos.Métodos: Estudo de coorte retrospectivo realizado em uma unidade de terapia intensiva pediátrica de um hospital universitário do Rio Grande do Sul. Foram analisadas as intervenções farmacêuticas realizadas entre março de 2016 a julho de 2018 por farmacêuticos clínicos. Tais intervenções foram reclassificadas conforme os critérios de um instrumento de acompanhamento farmacêutico (bundle) utilizado na rotina. Foi realizada análise estatística descritiva das variáveis estudadas.Resultados: Das 582 intervenções farmacêuticas analisadas, as categorias mais prevalentes foram dose (n = 97; 16,7%), necessidade (n = 92; 15,8%) e forma farmacêutica (n = 56; 9,6%). Após reclassificação das intervenções farmacêuticas utilizando o bundle, os critérios mais prevalentes foram: critério 1 (revisão da farmacoterapia; n = 285; 49%), critério 4 (analgesia; n = 78; 13,4%) e critério 10 (antimicrobianos; n = 65; 11,2%). As classes de medicamentos mais frequentes foram os do sistema nervoso (n = 213; 36,6%) e os anti-infecciosos gerais para uso sistêmico (n = 115; 19,8%). A taxa de adesão das intervenções farmacêuticas pela equipe médica foi de 85,1%.Conclusão: A classificação das intervenções farmacêuticas utilizando o bundle pode contribuir no aperfeiçoamento do instrumento tornando-o mais viável para uso na unidade de terapia intensiva pediátrica e direcionar o trabalho do farmacêutico clínico nas situações que geram mais problemas relacionados a medicamentos.


Introduction: Pharmaceutical interventions in the pediatric setting are highly peculiar due to the use of off-label drugs associated with the lack of scientific studies on the use of drug therapies in this population. Thus, clinical pharmacists may help identify and prevent drug-related problems.Methods: We conducted a retrospective cohort study in the pediatric intensive care unit of a teaching hospital in Rio Grande do Sul, Brazil. Pharmaceutical interventions conducted between March 2016 and July 2018 were analyzed by clinical pharmacists. These interventions were reclassified according to the criteria of a routine pharmaceutical monitoring instrument (care bundle). We conducted a descriptive statistical analysis of study variables.Results: Of 582 pharmaceutical interventions analyzed, the most prevalent categories were dose adjustment (n = 97; 16.7%), need for drug therapy (n = 92; 15.8%), and dosage forms (n = 56; 9.6%). After reclassification of pharmaceutical interventions, the most prevalent criteria were criterion 1 (review of drug therapy; n = 285; 49%), criterion 4 (analgesia; n = 78; 13.4%), and criterion 10 (antimicrobials; n = 65; 11.2%). The most common drug classes were nervous system agents (n = 213; 36.6%) and anti-infectives for systemic use (n = 115; 19.8%). The rate of adherence to pharmaceutical interventions by the medical team was 85.1%.Conclusions: The classification of pharmaceutical interventions according to the pharmaceutical care bundle may help improve the instrument, allowing its use in the pediatric intensive care unit and guiding clinical pharmacists in situations causing drug-related problems.


Assuntos
Humanos , Criança , Assistência Farmacêutica/estatística & dados numéricos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/tratamento farmacológico , Prevenção de Doenças , Unidades de Terapia Intensiva Pediátrica/organização & administração , Estudos de Coortes
2.
Clin. biomed. res ; 41(1): 18-26, 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1255087

RESUMO

Introduction: Care bundles help healthcare professionals provide the best care possible in a structured and reliable way. The purpose of this study was to develop and apply an instrument for inpatient follow-up by clinical pharmacists, and evaluate its results. Methods: The care bundle was based on previously validated instruments. Population consisted of patients monitored by clinical pharmacists at a general hospital. The study was conducted in two phases: the first involved the development and implementation of the bundle, and the evaluation of pharmaceutical interventions; the second involved analyzing data from patients treated with the bundle over one year. Results: The bundle included fourteen pharmaceutical follow-up criteria used in different patterns by each area of care. In the first phase of the study, 3263 patients were monitored and 536 pharmaceutical interventions were performed, with an 85.3% compliance rate. In the second phase of the study, follow-up data was collected from 21,214 patients. The bundle criteria were used in a similar way in clinical, surgical and cancer patients. Pharmacotherapy review was the most prevalent intervention in all cases (60.1%). Hospital discharge planning and medication reconciliation were performed with a similar frequency in clinical, surgical, pediatric and general patients. Conclusions: The development and validation of a bundle aimed at guiding the clinical activities of pharmacists helped standardize procedures and interventions. Pharmacotherapy review was the bundle criterion with the highest rate of application and interventions due to the hospital's complexity and the need to consider individual patient needs and follow institutional policies. (AU)


Assuntos
Humanos , Assistência Farmacêutica , Continuidade da Assistência ao Paciente , Pacotes de Assistência ao Paciente , Adesão à Medicação
3.
Pediatr Infect Dis J ; 38(9): 934-938, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31232892

RESUMO

BACKGROUND: A recent systematic review concluded that critically ill pediatric patients have higher odds of vancomycin-related nephrotoxicity [odds ratio (OR): 3.61, 95% CI: 1.21-10.74]. We aimed to assess the incidence and risk factors for vancomycin-associated nephrotoxicity in critically ill children without preexisting renal injury. METHODS: A cohort of children admitted to a pediatric intensive care unit, from 2011 to 2016 treated with vancomycin without preexisting renal injury. The main diagnosis, therapeutic interventions and medications administered in this period were evaluated. Generalized estimating equation models were used to assess the association between clinical covariates and the dependent variable pediatric risk, injury, failure, loss, end-stage renal disease (pRIFLE). RESULTS: Hundred ten patients, representing 1177 vancomycin days, were analyzed. Vancomycin-associated nephrotoxicity was seen in 11.8%. In a multivariate model, higher vancomycin doses were not associated with poorer renal function (P = 0.08). Higher serum vancomycin levels were weakly associated with pRIFLE classification (OR: 1.05, 95% CI: 1.02-1.07). Furosemide or amphotericin B in addition to the vancomycin treatment was associated with impaired renal function (OR: 2.56, 95% CI: 1.38-4.8 and OR: 7.7 95% CI: 2.55-23, respectively). CONCLUSIONS: Vancomycin-associated nephrotoxicity in acute ill children without preexisting renal injury, measured with pRIFLE, is close to 11.8%. Furosemide and amphotericin B in addition to the vancomycin treatment are strong predictors of worse pRIFLE scores. The influence of acute kidney injury status at pediatric intensive care unit admission and the method used for renal function assessment might influence the incidence of vancomycin-associated nephrotoxicity and its associated risk factors.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Antibacterianos/toxicidade , Unidades de Terapia Intensiva Pediátrica/estatística & dados numéricos , Rim/efeitos dos fármacos , Vancomicina/toxicidade , Doença Aguda , Antibacterianos/sangue , Criança , Pré-Escolar , Estado Terminal , Registros Eletrônicos de Saúde , Feminino , Humanos , Lactente , Masculino , Modelos Estatísticos , Razão de Chances , Estudos Retrospectivos , Fatores de Risco , Vancomicina/sangue
4.
Eur J Clin Pharmacol ; 65(12): 1253-8, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19669738

RESUMO

OBJECTIVE: To evaluate the utilization of chloral hydrate (CH) for sedation in pediatric intensive care and the incidence of adverse drug reactions. METHODS: This was a cohort study including patients with prescription of chloral hydrate hospitalized in the pediatric intensive care unit (PICU) of a university-affiliated, general, tertiary teaching hospital. Data were collected from a spreadsheet for daily monitoring, and clinical events registered in the patient records were analyzed to evaluate the causality of suspected adverse drug reactions (ADR), applying the Naranjo algorithm. RESULTS: Three hundred forty-three patients who had been prescribed CH were studied. Ages ranged from 0 to 18 years, and 63% were male. The most frequent cause for PICU admission was bronchiolitis (77.6%), and 58.6% required mechanical ventilation. In 92.7% of cases, CH was indicated to control agitation and in 7.3% for procedural sedation. The median time of CH use was 6 days. The incidence of suspected ADR was 22.7% ± 2.3. Oxygen desaturation was the most frequent adverse event (64.6%), followed by hypotension. Specific treatment was required in 60.9% of the events. Chloral hydrate as cause for suspected ADR was classified as probable in 39 events (35.5%) and as possible in 70 (63.6%), and no event was classified as definite. In the multivariate analysis, only mechanical ventilation was predictive of ADR to CH. CONCLUSIONS: The study described the clinical practice of sedation with CH in the PICU setting of a tertiary teaching hospital in southern Brazil. Data suggest that CH is an alternative for prolonged sedation in PICU


Assuntos
Hidrato de Cloral/administração & dosagem , Hidrato de Cloral/efeitos adversos , Sedação Consciente/efeitos adversos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/efeitos adversos , Adolescente , Brasil , Criança , Pré-Escolar , Estudos de Coortes , Sedação Consciente/métodos , Sedação Consciente/estatística & dados numéricos , Feminino , Hospitais de Ensino , Humanos , Lactente , Unidades de Terapia Intensiva Pediátrica , Masculino
5.
Artigo em Português | LILACS | ID: lil-552653

RESUMO

Objetivo: O objetivo deste trabalho foi descrever as atividades passivas realizadas por um Centro de Informações sobre Medicamentos (CIM) de hospital universitário no sul do Brasil. Resultados: de 2002 a 2008, o total de solicitações recebidas foi de 8035, das quais 30,3% foram realizadas por enfermeiros, 24,3% por farmacêuticos e 15% por técnicos de enfermagem. O tempo gasto para a resposta foi em 56,8% das vezes de até 10 minutos. Os temas mais solicitados foram administração de medicamentos (25,6%), identificação do produto (16,4%), posologia (10,6%) e estabilidade (9,6%). Conclusão: O CIM é uma estratégia na busca pelo uso seguro e racional de medicamentos nos hospitais.


Aim: The aim of this study was to describe the passive activities of Drug Information Center (DIC) of a university hospital in southern Brazil. Results: From 2002 to 2008, the total of requests was 8035, of which 30.3% were answered by nurses, 24.3% pharmacists and 15% technical nursing. The time spent to response was less than 10 minutes in 56.8%. The principal requests were about drug administration (25.6%), identification of the product (16.4%), dosage (10.6%) and stability (9.6%). Conclusion: The DIC is a strategy in the search for safe and rational use of drugs in hospitals.


Assuntos
Humanos , Preparações Farmacêuticas/provisão & distribuição , Racionalização , Serviços de Informação sobre Medicamentos/organização & administração , Serviços de Informação sobre Medicamentos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...